BPG is committed to discovery and dissemination of knowledge
Clinical Trials Study
©The Author(s) 2026.
World J Gastroenterol. Feb 7, 2026; 32(5): 113505
Published online Feb 7, 2026. doi: 10.3748/wjg.v32.i5.113505
Table 2 Initial infliximab clearance, probability of mucosal healing, probability of C-reactive protein normalization, and probability of antidrug antibody for patients who received Bayesian model-guided treatment
Patients
CL (L/day)
Probability of MHEAL
Probability of CRP normalization
Probability of ADA
10.62367.4219.1994.47
31.11020.733.95100.00
40.316039.4447.7856.62
50.016873.3270.2218.14
60.272246.5052.4947.96
70.393728.1839.4271.38
80.63297.0718.5694.78
90.60957.9420.1593.99
110.428823.9535.9976.34
120.512514.8228.1386.66


Write to the Help Desk